Viewing nowCombinationDapafopamine Sustained-release Tablet 10/500 mg
Dapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 202300366 · Approved 2023.01.27 · Insurance code 669908340
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with meals and exercise to help adults with type 2 diabetes control their blood sugar when using dapagliflozin and metformin together. It is particularly suitable for patients with insufficient blood sugar control who have cardiovascular diseases or risk factors for cardiovascular diseases. This medication can improve blood sugar control and assist in cardiovascular health management. However, it is recommended to refer to the professional information for detailed information related to cardiovascular events. Therefore, this medication is used to effectively improve blood sugar management in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no previous experience of antidiabetic drug therapy and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no previous experience of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously taking. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. As changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an active ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Metformin is excreted through the kidneys, and renal function is more likely to decline in elderly patients; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients, patient subsection).
This medication is used for diabetes treatment and should not be administered to patients with poor kidney function or impaired liver function. It can rarely cause a serious condition called lactic acidosis; therefore, it should be used cautiously while regularly undergoing tests related to kidney function. When used with insulin or sulfonylurea medication, there is a risk of hypoglycemia, so blood sugar levels should be checked frequently, and dosage adjustments may be necessary. Patients with reduced fluid volume or those at risk of low blood pressure should carefully monitor for dehydration symptoms or changes in blood pressure while using this medication. This medication may increase the risk of genital infections or urinary tract infections. If infection symptoms appear, consult a doctor immediately. Women who are pregnant or breastfeeding should not use this medication and should discontinue administration if pregnancy is planned or confirmed. Elderly patients have a higher risk of renal function decline, so the dosage of this medication should be determined carefully, and kidney function should be monitored regularly. During administration of this medication, excessive alcohol consumption should be avoided, and administration should be paused for a certain period before and after surgery or iodinated radiation imaging tests. In case of overdose, seek medical attention immediately for appropriate treatment, as this medication is eliminated through the kidneys, so monitoring kidney function is important. This medication has not been established for safety and efficacy in children and should not be used in this population. Additionally, this medication may cause vitamin B12 deficiency, so it is advisable to monitor blood vitamin B12 levels during long-term use. During usage, be cautious of dizziness or hypoglycemia symptoms, especially when driving or operating machinery. This medication should be stored in its original container and kept in a safe place out of the reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advised to keep it at room temperature, between 1 degree and 30 degrees Celsius.
Pink, convex on both sides, rectangular sustained-release film-coated tablet
30 tablets/box [6 tablets/PTP (Alu-Alu) × 5]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.